- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04908267
How the Precise Habitats Can Predict the IDH Mutation Status and Prognosis of the Patients With High-grade Gliomas
To Determine Whether the Habitats Created by the Preoperative or Postoperative Multiparametric MRI Can Predict IDH Mutation Status, Prognosis, Recurrence or Intracranial Distant Recurrence of the Patients With High-grade Gliomas
High-grade glioma is the most common primary malignant tumor in central nervous system, and its high tumor heterogeneity is the main cause of tumor progression, treatment resistance and recurrence. Habitat imaging is a segmentation technique by dividing tumor regions to characterize tumor heterogeneity based on tumor pathology, blood perfusion, molecular characteristics and other tumor biological features.
In some studies, the Hemodynamic Multiparametric Tissue Signature (HTS) method has been proven to be feasible. The Hemodynamic Multiparametric Tissue Signature (HTS) consists of a set of vascular habitats obtained by Dynamic Susceptibility Weighted Contrast Enhanced Magnetic Resonance Imaging (DSC-MRI) of high-grade gliomas using a multiparametric unsupervised analysis method. This allowed them to automatically draw 4 reproducible vascular habitats (High-angiogenic enhancing tumor; Low-angiogenic enhancing tumor; Potentially tumor infiltrated peripheral edema; Vasogenic peripheral edema) which enable to describe the tumor vascular heterogeneity robustly.
In other studies, contrast-enhancing mass can divided into spatial habitats by K-means clustering of voxel-wise apparent diffusion coefficient (ADC) and cerebral blood volume (CBV) values to observe the changes of voxels in spatial habitat on the time line. Using this so-called spatiotemporal habitat to identify progression or pseudoprogression in cancer therapy.
Above all, we have sufficient and firm reasons to deem that habitat imaging based on multiparametric MRI is more conducive to reflect the potential biological information inside the tumor and realize individualized diagnosis and treatment.
To sum up, the assumption of this experiment is that the Habitats Created by preoperative or postoperative Multiparametric MRI ,such as conventional MRI sequences, Dynamic Susceptibility Weighted Contrast Enhanced Magnetic Resonance Imaging (DSC-MRI), Dynamic Contrast Enhanced Magnetic Resonance Imaging (DCE-MRI), Diffusion Weighted Magnetic Resonance Imaging(DWI) ,Vessel Size Imaging (VSI) ,or Magnetic Resonance Spectroscopy (MRS) can predict the molecular mutation status, prognosis, treatment residence, progression, pseudoprogression, and even recurrence and distant intracranial recurrence in patients with high-grade gliomas.
Study Overview
Status
Conditions
Detailed Description
This is a single center experiment. The subjects of this study were patients diagnosed as high-grade glioma by multiparametric magnetic resonance imaging and pathological biopsy from January 1, 2008 to December 31, 2021(or at some interval within this period). Patients meeting the inclusion criteria will enter the next experimental stage.
- Patients selection: The patients will be clustered according to the preoperative and postoperative examination methods performed by each patient, such as only DSC sequence, both DSC and DWI sequences, or a full set of functional imaging sequences at the same time;
- Images segmentation: To select the patients who meet the experimental design, and use deep learning-based biomedical image segmentation methods, such as Brain Tumor Segmentation (BraTS) challenge, to segment more accurate and reproducible habitats as much as possible;
- Construction of clinical model: We may be able to obtain the parameter values of the habitat, such as CBV, ADC, Ktrans, etc. Combining these data with the basic situation of patients can build a clinical model.
- Construction of radiomics model: The radiomics analysis will probably be structured into four parts: habitats segmentation, feature extraction, feature selection and model construction.
- We try to analyze that habitat imaging based on Multiparametric MRI is indeed better than the conventional rough and simple ROI analysis; We try to analyze the relation between the habitats and the IDH mutation status or MGMT promoter methylation status; We try to analyze the relation between the habitats and the overall survival (OS) of the patient; We try to analyze the habitats is conducive to differentiate recurrence from distant intracranial recurrence.
Finally, statistical methods and survival analysis were used to determine whether the habitat was statistically significant for IDH mutation status and prognosis. For example, receiver operating characteristic curve (ROC) analysis evaluated the potential of the spatial habitats in IDH mutation prediction. The Kaplan-Meier curve evaluates the validation of the diagnosis in OS prediction in high-grade glioma.
Study Type
Enrollment (Anticipated)
Contacts and Locations
Study Contact
- Name: Jiachen Liu, M.D.
- Phone Number: (+86)18434161824
- Email: JCliu0430@163.com
Study Locations
-
-
Chongqing
-
Chongqing, Chongqing, China, 400042
- Recruiting
- Department of Radiology, Daping Hospital of Army Medical University
-
Contact:
- Jiachen Liu, master
- Email: jcliu0430@163.com
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
Description
Inclusion Criteria (if we will predict the molecular status and overall survival):
- the patient was over 18 years old
- the lesion was located in the supratentorial space;
- a histopathologic diagnosis of HGGs according to the WHO CNS4/5;
- all subjects were the first diagnosed cases without any invasive or non-invasive treatment;
- access to the complete preoperative MR imaging examinations, at least including four conventional sequences.
Inclusion Criteria (if we will differentiate recurrence from distant intracranial recurrence):
- the patient was over 18 years old;
- the lesion was located in the supratentorial space;
- a histopathologic diagnosis of HGGs according to the WHO CNS4/5;
- underwent concurrent chemoradiotherapy with temozolomide after surgical resection or biopsy;
- underwent preoperative and postoperative MRI, at least including four conventional sequences;
- had newly appeared or enlarging, measurable, contrast-enhancing mass which raises clinical suspicion of tumor recurrence and distant intracranial recurrence;
- adequate follow-up examinations to determine treatment response on clinic-radiological consensus or pathologic confirmation.
Exclusion Criteria:
- patient with other brain tumors or other grade gliomas at the same time;
- patient with severe basic diseases at the same time;
- patient with a survival time of less than 30 days, which can be caused by severe surgical trauma stress;
- poor image quality and heavy artifact affect the subsequent image processing.
Study Plan
How is the study designed?
Design Details
- Observational Models: Case-Only
- Time Perspectives: Retrospective
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Multi-model habitats constructed by multiparametric MRI predict IDH mutation status and the prognosis in high-grade gliomas
Time Frame: From the date of operation until the date of death from any cause,assessed up to 120 months
|
The IDH status of each patient was dependent on pathological and immunohistochemical results.
The overall survival for each patient is estimated since the date of operation to the end of recruitment.
The overall survival will be confirmed through clinical follow-up.
|
From the date of operation until the date of death from any cause,assessed up to 120 months
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Weiguo Zhang, Ph.D, Daping Hospital and the Research Institute of Surgery of the Third Military Medical University
Publications and helpful links
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 2022198
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on High-grade Glioma
-
Fondazione I.R.C.C.S. Istituto Neurologico Carlo...Federico II UniversityRecruitingHigh Grade Glioma | High Grade Glioma (III or IV)Italy
-
Beijing BiotechRecruitingGlioblastoma | Malignant Glioma | Recurrent Glioblastoma | High-grade Glioma | Recurrent High-grade GliomaChina
-
Eben RosenthalVanderbilt-Ingram Cancer CenterRecruitingGlioma | Brain Cancer | High Grade Glioma | High Grade Glioma (HGG) of the Brain With BRAF Aberration | High Grade Gliomas | High Grade Glioma (III or IV) | HGGUnited States
-
Nationwide Children's HospitalDay One Biopharmaceuticals, Inc.Not yet recruitingHigh Grade Glioma | WHO Grade 3 Glioma | Diffuse Intrinsic Pontine Glioma | Metastatic Brain Tumor | High Grade Glioma (HGG) of the Brain With BRAF Aberration | High Grade Glioma (III or IV) | WHO Grade 4 Glioma
-
Sabine Mueller, MD, PhDNot yet recruitingGlioblastoma | Diffuse Midline Glioma, H3 K27M-Mutant | High-grade Glioma | High-Grade Glioma (WHO III-IV) | Diffuse Hemispheric Glioma, H3G34 MutantUnited States
-
James FelkerConnor's Cure; Ellie Kavalieros Fund; Translational Brain Tumor Research FundCompletedNewly Diagnosed Pediatric Pontine Glioma | Newly Diagnosed Pediatric High Grade Glioma | Recurrent Pediatric High Grade Glioma | Recurrent Pediatric Low Grade GliomaUnited States
-
Beijing BiotechRecruitingGlioblastoma | Malignant Glioma | Recurrent Glioblastoma | Recurrent High-Grade Gliomas | High-Grade GliomasChina
-
Tcelltech Inc.Mayo Clinic; Beijing Tiantan HospitalRecruitingHigh-grade Glioma | WHO Grade Ⅳ GliomaUnited States, China
-
The University of Texas Health Science Center at...CompletedHIGH GRADE GLIOMAUnited States
-
National Cancer Institute (NCI)SuspendedGlioma | High Grade Glioma | Malignant Glioma | Gliomas | Low Grade GliomaUnited States